Yasemin Bakkal Temi

Dr. Yasemin Bakkal Temi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2023 in Medicine
Verified
Journal Article
Open access
ESElif Sahin
Elif Sahin
UKUmut Kefeli
Umut Kefeli
ŞZŞevket Zorlu
Şevket Zorlu
MSMustafa Seyyar
Mustafa Seyyar
MAMutianur Ozkorkmaz Akdag
Mutianur Ozkorkmaz Akdag
KUKazim Uygun
Kazim Uygun
This study is aimed to investigate the prognostic significance of inflammation indices, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV) in metastatic castration-resistant prostate cancer (mCRPC) patients who had received lutetium labeled prostate-specific membrane antigen (177Lu–PSMA-617) therapy. Sixty-one mCRPC patients who received 177Lu–PSMA-617 treatment and followed up in Kocaeli University were included. The relationship between overall survival (OS) and progression-free survival (PFS) and clinical and laboratory parameters was analyzed by multivariate analyses. The mean age was 69.8 ± 6.9 years. The mean follow-up time was 53.2 ± 24 months. The median OS was 14 (95% CI: 8.8–18.1) and the median PFS was 10.4 (95% CI: 4.7–17.2) months. NLR ≥ 2.7, PLR ≥ 134.27, SII ≥ 570.39, PIV ≥ 408.59 were considered as elevated levels. In the multivariate analysis for OS, baseline ECOG performance score (HR: 1.92, 95% CI: 1.01–3.65, P = .046), high albümin (HR: 0.36, 95% CI: 0.16–0.82, P = .015), primary resistant total prostate-specific-antigen (PSA) (HR: 4.37, 95% CI: 1.84–10.35, P = .001), high NLR (HR: 3.32, 95% CI: 1.66–6.65, P = .001), high MLR (HR: 2.53, 95% CI: 1.35–4.76, P = .004), high PLR (HR: 2.47, 95% CI: 1.23–4.96, P = .01), and high SII (HR: 2.17, 95% CI: 1.09–4.32, P = .027) were associated with shorter OS. However, PIV was not associated with survival (P = .69). No factor other than the primer-resistant PSA could be identified as having an impact on PFS (for the PSA, HR: 4.52, 95% CI: 1.89–10.76, P = .001). In this study, pretreatment NLR, MLR, PLR, and SII demonstrate as powerful independent prognostic indices predicting survival in patients with mCRPC receiving 177Lu–PSMA-617 therapy.

31 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
İÇİlkay Çıtakkul
İlkay Çıtakkul
UKUmut Kefeli
Umut Kefeli
KSKhatira Shukurova
Khatira Shukurova
ZAZehra Aytin
Zehra Aytin
YTYasemin Bakkal Temi
Yasemin Bakkal Temi
DCDevrim Cabuk
Devrim Cabuk
Background/Objectives: Preoperative prognostic assessment is essential for optimizing treatment strategies in pancreatic ductal adenocarcinoma (PDAC). This study aimed to evaluate and compare the prognostic value of the Heidelberg Pancreatic Prognostic (HELPP) score and the C-reactive protein–albumin–lymphocyte (CALLY) index in patients with resectable PDAC. Methods: We retrospectively analyzed clinical and laboratory data of 109 patients with resectable PDAC who underwent curative-intent surgery and adjuvant therapy. Patients were stratified based on preoperative HELPP and CALLY scores. Overall survival (OS) and disease-free survival (DFS) were assessed using Kaplan–Meier analysis, while independent prognostic factors were determined through multivariate Cox regression. Results: Kaplan–Meier survival analyses demonstrated that a HELPP score > 3 and a low CALLY index (≤1.029) were significantly associated with worse OS and DFS (log-rank p < 0.05). In multivariate analysis, the HELPP score was identified as an independent predictor of survival, whereas the CALLY index, although associated with survival in univariate analysis, did not reach statistical significance. In ROC analysis, both models exhibited acceptable discrimination, with the HELPP score achieving superior AUC values in predicting 1-year OS compared to the CALLY index. Conclusions: The HELPP score demonstrated independent prognostic value in multivariate analysis and may serve as a robust preoperative tool in resectable PDAC. The CALLY index, although not independently significant in multivariate analysis, showed strong prognostic separation in Kaplan–Meier survival analyses and may still aid in preoperative risk stratification, particularly where access to comprehensive scoring systems is limited.

Verified
Journal Article
Open access
PDF file
MSMustafa Seyyar
Mustafa Seyyar
PŞPervin Can Şancı
Pervin Can Şancı
TKTolga Köşeci
Tolga Köşeci
AKAnıl Karakayalı
Anıl Karakayalı
MAMutianur Özkorkmaz Akdağ
Mutianur Özkorkmaz Akdağ
DCDevrim Cabuk
Devrim Cabuk
Objectives: Inflammation plays an important role in cancer development, and various inflammation parameters are used as potential prognostic markers. This study aimed to evaluate the effectiveness of the combined use of HALP and H index in predicting pathological response to neoadjuvant therapy in patients with HER2-positive early-stage breast cancer. Method: This retrospective cohort study was conducted on 146 HER2-positive breast cancer patients treated in two centers. To stratify patients by their predicted probability of pathological response, HALP and H index values were combined into a composite biomarker score called the combined response score (CRS). Patients were classified into three groups based on biomarker levels: 0 = low CRS (low predictive score), 1 = intermediate CRS, and 2 = high CRS (high predictive score). These groups reflect predicted response likelihood and do not represent actual pathological outcomes. Pathological response results were evaluated according to the combined response score. Pathological complete response (pCR) was defined as residual cancer burden (RCB) 0, indicating no residual invasive tumor in breast or lymph nodes. Results: The mean age of 146 early-stage breast cancer patients included in our study was 52.3 ± 11.3 (min: 29-max: 83). In the ROC analysis, the optimum cut-off value for the HALP score in pathological response classification was found to be 36 (AUC = 0.608, sensitivity = 76.29%, specificity = 44.9%, PPV = 73%, NPV = 47.89%) and 2.3 for the H index (AUC = 0.641, sensitivity = 65.98%, specificity = 51.02%, PPV = 72.73%, NPV = 43.1%). While the pathological complete response rate was 66.4% in all patients, it was 81.8% in those with a combined score of 2, 51% in those with a score of 1, and 58.6% in those with a score of 0 (p < 0.001). In the logistic regression analysis, the probability of pathological response in patients in the combined score = 2 group is 3.77 times higher than in group 0. In the Fagan nomogram, the pretest probability of pathological response is 66%, while the post-test probability for combined response score group 2 is 81.5%, and for the low-H index < 2.3 and the high-HALP ≥ 36 patient group, our estimate for pathological complete response increases to 82%. Conclusions: The HALP-H index combined score is an important predictor of pathological response in early-stage HER2-positive breast cancer patients, independent of histological type and stage. This new score may enable personalized approaches in treatment planning.

22 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BKBaris Koksal
Baris Koksal
HYHasan Çağrı Yıldırım
Hasan Çağrı Yıldırım
DGDeniz Can Guven
Deniz Can Guven
FKFatih Köse
Fatih Köse
GKGörkem Köymen
Görkem Köymen
ZAZafer ARIK
Zafer ARIK
Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have been established as a first-line maintenance therapy in advanced epithelial ovarian cancer (EOC) following platinum-based chemotherapy. While phase III trials have demonstrated significant progression-free survival (PFS) benefits with olaparib and niraparib, real-world data remain limited. Methods: This retrospective, multicenter real-world study included 179 patients with newly diagnosed epithelial ovarian treated with first-line maintenance olaparib or niraparib across 33 centers in Türkiye between January 2014 and March 2025. Clinical, pathological, and molecular data—including BRCA (Breast Cancer Susceptibility Gene) mutation status, origin, and variant classification—was collected. The primary endpoint was PFS, and secondary endpoints included overall survival (OS) and safety. Survival outcomes were analyzed using Kaplan–Meier methods. Results: Of 179 patients, 110 received olaparib and 69 received niraparib. BRCA mutations were present in 88.3% of patients, while 11.7% had unknown HRD status. Median follow-up was 16.5 months, and median PFS was not reached. Estimated PFS rates for the overall cohort were 91.0% at 6 months, 83.0% at 12 months, and 64.0% at 24 months. In the olaparib cohort, BRCA-mutant patients demonstrated PFS rates of 89%, 78%, 73%, and 64% at 6, 12, 18, and 24 months, respectively. In the niraparib cohort, corresponding PFS rates among BRCA-mutant patients were 87% at 6 months and 75% at 12 months. Patients harboring pathogenic BRCA variants experienced longer PFS compared with those with likely pathogenic variants. Any-grade adverse events occurred in 73.7% of patients, and grade 3–4 events in 29.6%, with hematologic toxicities predominating. Dose interruptions were more frequent with niraparib, while treatment discontinuation rates were low in both groups. No cases of myelodysplastic syndrome or acute myeloid leukemia were observed. Conclusions: In this large multicenter real-world cohort, first-line maintenance therapy with olaparib and niraparib provided durable PFS benefit in patients with advanced EOC, particularly among those with pathogenic BRCA mutations, confirming their effectiveness and manageable safety profiles in routine clinical practice.

1 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Closed access
YTYasemin Bakkal Temi
Yasemin Bakkal Temi
İÇİlkay Çıtakkul
İlkay Çıtakkul
EBEce Baydar
Ece Baydar
SBSibel Balci
Sibel Balci
DCDevrim Cabuk
Devrim Cabuk
KUKazım Uygun
Kazım Uygun
Aim: We evaluated the prognostic significance of the KELIM score, which is derived from CA-125 kinetics, in predicting survival outcomes among patients with advanced epithelial ovarian cancer in a real-world clinical context. Material and Methods: This retrospective study analyzed 238 patients with stage III-IV ovarian cancer treated between 2017-2024. KELIM scores, calculated from CA-125 kinetics during the first 100 treatment days, were categorized as high (favorable, >0.9) or low (unfavorable, ≤0.9) based on the ROC analysis. Survival outcomes were assessed using Kaplan-Meier and Cox regression analyses. Results: Patients with low KELIM scores had significantly shorter median overall survival (33 vs. 68 months, p < 0.001) and progression-free survival (11 vs. 18 months, p < 0.001) than those with high scores. Multivariate Cox regression analysis identified a low KELIM score as a significant predictor of poor overall survival (HR, 4.062; 95% CI, 2.711–6.087; p < 0.001). Additionally, disease progression was more frequent in patients with a low KELIM score (89.4%) than in those with a high KELIM score (69.9%, p = 0.001). Conclusion: The KELIM score serves as a practical and accessible prognostic biomarker for advanced ovarian cancer with the potential to inform early treatment decisions for patients who are unlikely to benefit from standard chemotherapy. Further prospective studies are warranted to validate their roles in personalized therapeutic strategies.

16 September 2025 in Frontiers in Psychology
Verified
Journal Article
Open access
PDF file
YTYasemin Bakkal Temi
Yasemin Bakkal Temi
AGAila Gareayaghi
Aila Gareayaghi
EBEce Baydar
Ece Baydar
IÇİlKay Çıtakkul
İlKay Çıtakkul
DÇDevrim Çabuk
Devrim Çabuk
KUKazım Uygun
Kazım Uygun
Objectives: Significant psychological distress is prevalent among patients with advanced gastrointestinal cancer, underscoring the need to investigate the roles of mindfulness and coping strategies in shaping emotional outcomes. However, this relationship has not yet been sufficiently explored. Therefore, this study aimed to investigate the associations between mindfulness, coping styles, and emotional distress (anxiety and depression) in individuals with advanced gastrointestinal cancer.Methods: This cross-sectional study enrolled 110 patients with stage IV gastrointestinal cancer who received palliative chemotherapy. Participants completed Turkish versions of the Mindful Attention Awareness Scale, Mental Adjustment to Cancer scale, and Hospital Anxiety and Depression Scale. Sociodemographic and clinical data were collected using a patient information form. Data were analyzed using non-parametric tests and correlation analyses to examine group differences and associations among study variables.Results: Our findings indicated significant associations between trait mindfulness, coping strategies, and emotional symptoms. Specifically, trait mindfulness was positively correlated with adaptive coping (r = 0.245, p = 0.010) and anxiety (r = 0.455, p < 0.001), whereas it was negatively correlated with maladaptive coping (r = −0.326, p = 0.001). Moreover, participants who employed maladaptive coping strategies reported lower levels of mindfulness. No significant differences in depression were observed between coping style groups. Notably, the positive correlation between adaptive coping strategies and anxiety symptoms highlights the complex nature of the coping mechanisms.Conclusion: These findings underscore the importance of contextualizing coping constructs, and suggest that mindfulness, despite its paradoxical relationship with anxiety, may mitigate reliance on maladaptive strategies. Routine psychological screening and personalized psychosocial support should be incorporated into oncological care to facilitate emotional adjustment.